Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421353 · ClinicalTrials.gov registry record · Phase 1
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT03421353 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 76 participants.
The verdict
NCT03421353, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with advanced, solid tumours and subsequently in patients with non-small-cell lung cancer (NSCLC)
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Durvalumab
- DRUG AZD9150
- DRUG 5-Flourouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2024-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03421353
The ClinicalTrials.gov registry entry for NCT03421353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03421353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03421353 about?
NCT03421353 is a clinical study titled "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer". This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with advanced, solid tumours and subsequently in patients with non-small-cell...
What is the current status of trial NCT03421353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2018-02-07. Estimated completion is 2024-03-28.
What interventions are being tested in trial NCT03421353?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Durvalumab (DRUG), AZD9150 (DRUG), 5-Flourouracil (DRUG).
Who is sponsoring clinical trial NCT03421353?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.